Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 9/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10461147 | 1.00 | TYMP (0.48) | TYMPP2RY12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL13830309 | 0.93 | TYMP (0.49) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL13838270 | 0.93 | TYMP (0.49) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL20798309 | 0.93 | TYMP (0.49) | TYMPP2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL10460984 | 0.89 | TYMP (0.51) | TYMPADORA1 | |
| SCHEMBL10459534 | 0.89 | TYMP (0.51) | TYMPADORA1 | |
| SCHEMBL13459280 | 0.87 | TYMP (0.39) | TYMPP2RY12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL10457923 | 0.86 | TYMP (0.38) | TYMPP2RY12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL10461189 | 0.86 | TYMP (0.38) | TYMPP2RY12PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL10457914 | 0.84 | ADORA1 (0.51) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | TYMP 202/4885P2RY12 1456/4885PRKAG1 2125/4885 |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | NSUN2, SNRPB2, RNGTT | TYMP 202/4885P2RY12 1456/4885PRKAG1 2125/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | TYMP 91/4885P2RY12 2148/4885PRKAG1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.